> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Kratom Poison Reports Rose 1,200% as 7-OH Products Outran U.S. Rules
- URL: https://www.theamericanquorum.com/kratom-poison-reports-rose-1200-percent-7-oh-regulatory-gap/
- Published: 2026-09-25T12:20:34.000Z
- Updated: 2026-09-25T12:20:34.000Z
- Description: A South Carolina death exposes the national divide between botanical kratom, concentrated 7-OH and fragmented U.S. mortality tracking.
- Author: Kenneth R. Deans Jr.
- Tags: Healthcare, South Carolina, Colorado, California, Kansas, Texas

*TAQ Investigation*

LANCASTER, S.C. — When 29-year-old Micah Knox stopped answering his mother’s daily call on June 26, his parents feared that he had returned to an illicit drug. They told a South Carolina television station that he had been sober for nine and a half months and that they expected toxicology to show fentanyl or another familiar threat.

Instead, the [WIS report](https://www.wistv.com/2026/09/23/were-so-concerned-son-didnt-deserve-die-something-bought-gas-station-parents-say/?ref=theamericanquorum.com) said Knox’s death was ruled an accidental overdose involving mitragynine, the principal psychoactive alkaloid in kratom. His parents said no fentanyl was found. They believe a product bought legally at a gas station killed their son, and they are pressing for tighter controls.

The case captures a widening national hazard, but it also exposes a basic problem in the public discussion: “kratom” now describes products that can range from dried botanical leaf to chemically enhanced tablets containing potent concentrations of 7-hydroxymitragynine, or 7-OH. Those products do not carry the same pharmacology, yet death records, poison-center reports, retail labels and news accounts often place them in one category.

A TAQ review of federal mortality, poison-center, toxicology and regulatory records found strong evidence that kratom-associated harm is increasing, particularly as high-potency 7-OH products have spread. It also found that the available data cannot establish one nationwide kratom death toll, cannot calculate an individual user’s risk and often cannot determine which formulation a person consumed.

## Poison-center reports rose 1,200%

The newest national warning comes from the Centers for Disease Control and Prevention. In a March 2026 [CDC analysis](https://www.cdc.gov/mmwr/volumes/75/wr/mm7511a1.htm?ref=theamericanquorum.com) of all 53 U.S. poison centers, researchers identified 14,449 reported kratom exposures among people age 12 and older from 2015 through 2025\. The annual count climbed from 258 to 3,434 — an increase of approximately 1,200%.

The escalation was not limited to calls with mild symptoms. Hospitalizations tied to single-substance reports rose from 43 in 2015 to 538 in 2025\. Hospitalizations involving kratom plus other substances rose from 40 to 549\. Across the 11-year period, poison centers recorded 7,287 serious outcomes and 233 deaths associated with kratom reports.

Those 233 deaths require context. Of them, 184 — 79% — involved more than one substance. Opioids were reported in 62% of fatalities, benzodiazepines in 20%, stimulants in 20% and alcohol in 19%. The remaining 49 were coded as single-substance exposure reports, but that designation means kratom was the only substance reported to the poison center; it is not the same as a complete autopsy proving kratom was the sole cause.

The dataset also is not a census of every exposure. Poison centers learn about cases when a consumer, clinician or other caller contacts them. Reporting practices, product identification and follow-up vary. The data prove a sharp rise in reported harm, not the odds that any particular dose will be fatal.

## A second system counts far more deaths

Mortality surveillance produces a larger number because it asks a different question. A [Post review](https://www.washingtonpost.com/health/2024/02/20/kratom-deaths/?ref=theamericanquorum.com) of federal and state records found that medical examiners or coroners listed kratom as contributing to or causing at least 4,100 deaths in 44 states and the District of Columbia from 2020 through 2022.

A CDC analysis prepared for that review found kratom implicated in 663 fatal overdoses in 2020, 834 in 2021 and 846 in 2022 across 30 states and the District. Kratom was listed as the sole substance causing death in 58, 68 and 56 cases, respectively. Several populous states were outside the CDC subset, and most deaths involved other substances.

That tally should not be added to the poison-center count. One system records calls and their outcomes; the other abstracts medical-examiner and coroner findings. Testing is not uniform, and a detected substance is not necessarily a cause of death. An [older study](https://www.cdc.gov/mmwr/volumes/68/wr/mm6814a2.htm?ref=theamericanquorum.com) illustrates the distinction: among 152 overdose deaths in which kratom was detected in 2016 and 2017, medical examiners identified it as a cause in 91, while only seven had no other substance detected. Even in those seven, CDC cautioned that another substance could not be ruled out.

## “Kratom” is no longer one product

Traditional kratom comes from the leaves of *Mitragyna speciosa*, a Southeast Asian tree. Its dominant alkaloid, mitragynine, acts on several biological pathways and is converted in the body to 7-OH. At lower exposure levels, users may report stimulant-like effects; at higher levels, opioid-like effects can predominate.

People report using kratom for pain, anxiety, energy, opioid withdrawal and cravings. The National Institute on Drug Abuse estimates that about 1.7 million Americans age 12 or older used it in 2021\. Research into possible therapeutic compounds continues, but [NIDA says](https://nida.nih.gov/research-topics/kratom?ref=theamericanquorum.com) no kratom product has been demonstrated safe and effective for a medical condition. It also says a fatal overdose from kratom alone appears to be extremely rare.

That conclusion is not a declaration that all products labeled kratom are safe. Natural leaf typically contains only about 0.01% to 0.04% 7-OH by dry weight. The Food and Drug Administration says some newer tablets, gummies, shots and powders contain enhanced 7-OH that likely was produced by chemically converting mitragynine rather than simply extracting the trace amount in a leaf.

In its [FDA assessment](https://www.fda.gov/files/drugs/published/7-hydroxymitragynin%5F7-oh%5Fan%5Fassessment%5Fof%5Fthe%5Fscientific%5Fdata%5Fand%5Ftoxicological%5Fconcerns%5Faround%5Fan%5Femerging%5Fopioid%5Fthreat.pdf?ref=theamericanquorum.com), the agency describes 7-OH as a potent mu-opioid receptor agonist. Preclinical studies found respiratory depression, physical dependence, withdrawal and reinforcing effects characteristic of opioids. Some laboratory and animal models found greater potency than morphine, but that does not translate into a simple claim that every retail product is a fixed number of times stronger in a human being.

This distinction resolves what can sound like a contradiction: botanical kratom by itself has rarely been established as the sole cause of a fatal overdose, while concentrated 7-OH can present an opioid-like respiratory risk and an uncertain dose. Both statements can be true.

## Toxicology cannot always identify the product

The Knox case is an example of what remains unknown. The news report says mitragynine was found and attributes the death to an accidental mitragynine overdose. It does not publish the complete toxicology report, the product label, a laboratory analysis of the remaining product or a measured 7-OH concentration. Without those records, the public cannot independently determine whether Knox used leaf powder, an extract, an enhanced 7-OH product or another formulation.

Even a positive 7-OH test may not answer that question. Humans metabolize mitragynine into 7-OH. FDA warns that this makes postmortem 7-OH findings difficult to interpret unless investigators also have product chemistry, concentrations, scene evidence and a full toxicology panel.

The surveillance gap is nationwide. Specific poison-center codes for 7-OH were added only in early 2025\. DEA’s voluntary toxicology program examines leftover biological samples from selected fatal and nonfatal overdoses; it does not capture every case and frequently finds other drugs. FDA’s adverse-event system had received 13 suspected 7-OH reports, including two deaths, when it prepared its 2025 assessment, but the agency said product uncertainty, medications and underlying illness prevented confident attribution.

## Federal action remains incomplete

FDA’s legal position is unusually stark: kratom is not lawfully marketed in the United States as a drug, dietary supplement or conventional food additive. There are no FDA-approved prescription or over-the-counter kratom drugs. The agency has issued warnings, import alerts and seizures, including a December 2025 seizure of about 73,000 7-OH units valued at roughly $1 million. Yet products remain easy to find because food-and-drug enforcement and controlled-substance scheduling are different legal systems, and enforcement is not equivalent to a nationwide retail recall.

On July 6, 2026, DEA published a [July notice](https://www.federalregister.gov/documents/2026/07/06/2026-13580/schedules-of-controlled-substance-temporary-placement-of-7-hydroxymitragynine-above-a-specified?ref=theamericanquorum.com) of intent to place 7-OH above a specified threshold into Schedule I. The proposed threshold would cover botanical material above 0.05% 7-OH by dry weight and processed or synthetic articles above 0.05% or containing more than 1 milligram. The proposal expressly sought to leave ordinary botanical leaf below the threshold outside the action.

DEA separately placed three related manufactured compounds — mitragynine pseudoindoxyl, MGM-15 and MGM-16 — into Schedule I effective Aug. 26\. The [August order](https://www.justice.gov/opa/pr/justice-department-announces-emergency-scheduling-three-potent-opioid-compounds?ref=theamericanquorum.com) did not schedule botanical kratom or automatically complete the separate 7-OH threshold action.

As of Sept. 25, the federal materials reviewed by TAQ showed the July 7-OH notice of intent and the final August order for the three related compounds, but no corresponding final temporary order for threshold-level 7-OH itself. The distinction matters: announcing an intent to schedule a substance is not the same as an effective nationwide prohibition.

## State borders now change the rules

The result is a patchwork that can treat substantially similar packages in radically different ways.

- **South Carolina:** A 2025 [state law](https://www.scstatehouse.gov/sess126%5F2025-2026/bills/221.htm?ref=theamericanquorum.com) bars sales to anyone under 21, requires labels to state mitragynine and 7-OH amounts and prohibits fully synthetic alkaloids. It does not cap 7-OH concentration. The [Senate record](https://www.scstatehouse.gov/sess126%5F2025-2026/sj25/20250424.htm?ref=theamericanquorum.com) shows lawmakers struck a proposed 2% cap before passage. A broader 2026 [House bill](https://www.scstatehouse.gov/sess126%5F2025-2026/bills/4641.htm?ref=theamericanquorum.com) passed that chamber but has remained in the Senate Medical Affairs Committee since April 30.
- **Colorado:** Enacted [Colorado law](https://leg.colorado.gov/bills/SB25-072?ref=theamericanquorum.com) prohibits synthetic or semi-synthetic kratom alkaloids, products over a 2% 7-OH share of total alkaloids and child-appealing confections.
- **California:** State officials treat kratom and 7-OH foods and supplements as illegal under state food-and-drug law. A March 2026 [California enforcement](https://www.gov.ca.gov/2026/03/03/governor-newsom-announces-95-compliance-with-prohibition-of-illegal-kratom-products/?ref=theamericanquorum.com) update said agents removed 3,308 products from store shelves in three weeks.
- **Kansas:** An April 2026 [Kansas action](https://www.governor.ks.gov/Home/Components/News/News/1016/55?ref=theamericanquorum.com) placed 7-OH-related substances into Schedule I while distinguishing them from ordinary plant material.

South Carolina therefore requires a number on a label but permits concentrations that Colorado prohibits. California says the consumable products are already unlawful. Federal regulators have targeted particular enhanced and synthetic compounds but have not produced one settled national retail standard.

## What the evidence supports — and what it does not

The available evidence supports five conclusions.

1. Kratom-associated poison reports, hospitalizations and serious outcomes have risen sharply.
2. Deaths involving kratom are real, but most documented fatalities also involve opioids, benzodiazepines, stimulants, alcohol or other substances.
3. Fatal overdose attributed to botanical kratom alone appears uncommon, although inconsistent testing can miss cases.
4. Enhanced 7-OH products have opioid-like pharmacology, can depress breathing and are materially different from traditional leaf.
5. No available national dataset provides a reliable fatality rate per user, per product or per dose.

The evidence does not justify calling every kratom product “fentanyl,” nor does legal sale at a gas station establish safety. It does justify treating an unlabeled or high-dose 7-OH tablet, gummy or shot as an unpredictable opioid-like exposure rather than an ordinary herbal supplement.

## What to do in an emergency

Warning signs after kratom or 7-OH use can include extreme sleepiness, loss of consciousness, slowed or difficult breathing, confusion, agitation, vomiting or seizures. A [Texas advisory](https://www.dshs.texas.gov/news-alerts/serious-illnesses-associated-7-oh-use?ref=theamericanquorum.com) tells clinicians to provide emergency support and administer naloxone when respiratory depression is present.

If someone is unresponsive, is breathing abnormally or has a seizure, call 911 immediately. If opioid overdose is suspected and naloxone is available, administer it while emergency help is on the way. For a suspected exposure without immediate life-threatening symptoms, contact [Poison Control](https://www.poison.org/how-to-get-help-from-poison-control?ref=theamericanquorum.com) at 1-800-222-1222\. People concerned about dependence or withdrawal can reach the free, confidential [SAMHSA helpline](https://www.samhsa.gov/find-help/helplines/national-helpline?ref=theamericanquorum.com) at 1-800-662-HELP.

## The national gap is information

A credible national response does not require pretending that dried leaf and concentrated 7-OH are identical. It requires product-specific rules and product-specific data: standardized labels, batch testing, enforceable concentration limits, adverse-event reporting, consistent death-investigation toxicology and preservation of the package consumed in serious cases.

Micah Knox’s death cannot, from the public record alone, answer every scientific question about kratom. It does show the consequence of leaving those questions unanswered at the point of sale. A consumer can encounter a product with opioid-like effects in the same retail setting as candy or an energy drink, while regulators, physicians and medical examiners still lack a common system for identifying exactly what was taken.

That is the nationwide danger the numbers establish: not that every kratom exposure is lethal, but that rising use, concentrated chemistry and fragmented oversight have made preventable harm harder to recognize before it becomes fatal.